What Should You Anticipate in Amgen's Fourth Quarter 2025 Earnings Announcement

Amgen Inc.: Company Overview and Earnings Outlook

Based in Thousand Oaks, California, Amgen Inc. (AMGN) is a leading biotechnology company specializing in the discovery, development, production, and distribution of human therapeutics. With a market capitalization of $176.4 billion, Amgen is renowned for creating innovative medicines rooted in cellular and molecular biology. The company is preparing to release its financial results for the fourth quarter of 2025.

Anticipated Earnings Performance

Analysts project that Amgen will announce diluted earnings per share of $4.74 for the upcoming quarter, representing a 10.7% decrease compared to the $5.31 per share reported in the same period last year. Notably, Amgen has exceeded Wall Street’s EPS expectations in each of the past four quarters.

Full-Year and Future EPS Projections

For the entire fiscal year, experts anticipate Amgen will post earnings per share of $21.28, a 7.3% increase from the $19.84 reported in 2024. Looking ahead to 2026, EPS is forecasted to edge up by 1.9% to $21.69.

Stock Performance Comparison

Over the past year, Amgen’s stock has risen by 22.8%, outpacing the S&P 500 Index’s 16.2% gain. The company also exceeded the Health Care Select Sector SPDR Fund’s (XLV) 11.6% return during the same period.

Growth Drivers and Strategic Initiatives

Amgen’s robust performance is attributed to increased demand for newer therapies such as Repatha, Tezspire, and Evenity. The company’s broad product lineup, successful launches, and initiatives to expand patient access have contributed to double-digit growth in 16 different products. Management remains optimistic about future growth, citing a strong late-stage pipeline and ongoing investments in manufacturing and artificial intelligence, including the AmgenNow platform to enhance patient access.

Recent Financial Results

On November 4, 2025, Amgen announced its third-quarter results, leading to a 7.8% increase in its share price the following day. The company reported adjusted earnings per share of $5.64, surpassing analysts’ expectations of $5. Revenue reached $9.6 billion, also beating the projected $8.9 billion. For the full year, Amgen anticipates adjusted EPS between $20.60 and $21.40, with revenue expected to range from $35.8 billion to $36.6 billion.

Analyst Ratings and Price Targets

Market sentiment toward Amgen is generally positive, with analysts assigning a “Moderate Buy” consensus rating. Of the 32 analysts covering the stock, 14 recommend a “Strong Buy,” two suggest a “Moderate Buy,” 13 rate it as “Hold,” one advises a “Moderate Sell,” and two recommend a “Strong Sell.” The average price target stands at $330.74, implying a potential upside of 3.1% from current levels.